Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, et al
The Role of Obesity and Diabetes in Dementia
But what we wanted to understand is what theyre doing in the brain. Key findings GLP-1 drugs act not only on metabolic pathways but also on brain circuits linked to reward Researchers identified a pathway connecting the hindbrain, central amygdala and dopamine-producing neurons The drugs reduce not just hunger, but the desire for high-calorie, rewarding foods Findings may help explain both therapeutic benefits and side effects such as nausea or reduced pleasure Beyond appetite suppression GLP-1 receptor agonists were originally developed to treat Type 2 diabetes by improving insulin response, with weight loss emerging as a secondary benefit
GnRH agonists mimic the natural GnRH decapeptide hormone that is released by the hypothalamus to stimulate the secretion of the gonadotropin hormones
Sleep and stress Cortisol, the primary stress hormone, promotes fat storage and increases appetite